Deep-learning imaging technology to enhance Phase II trial
Biopharmaceutical company Rein Therapeutics and core imaging laboratory Qureight have announced plans to collaborate on an idiopathic pulmonary fibrosis (IPF) clinical trial.
The companies will integrate Qureight’s deep-learning platform into Rein’s planned Phase II trial of its lead asset LTI-03, a novel, multi-pathway, Caveolin-1-related peptide.
Rein previously announced positive topline results from Cohort 2 (5mg BID) of the Phase Ib clinical trial of LTI-03 in IPF.
In the trial, a positive trend was observed in seven out of eight biomarkers evaluated, with five biomarkers demonstrating dose-dependent effects and four biomarkers achieving statistical significance in the combined Cohort 1 and Cohort 2 data set.
The Phase II clinical trial of LTI-03 will continue to evaluate the safety, tolerability and efficacy of LTI-03 in IPF across multiple biomarkers and measure lung function and healthy tissue regeneration.
In the trial, Qureight will provide full end-to-end imaging core lab services, including site qualification, data handling, quality control and deep-learning AI image analysis, across 50 sites globally.
Qureight’s deep-learning platform will be used to analyse lung imaging data and identify correlations between any volumetric changes within the lungs of IPF patients and LTI-03’s efficacy.
AI tools will measure the volume of fibrotic, vascular and airway lung compartments, allowing a more detailed examination of LTI-03’s ability to simultaneously modulate pro-fibrotic activity and to protect critical alveolar epithelial cells.
Brian Windsor, President and Chief Executive Officer of Rein Therapeutics, said: “We are taking the evaluation of biomarkers a step further with the application of cutting-edge deep-learning imaging technology and detailed AI-based data analysis by collaborating with Qureight on this Phase II trial. These tools will be critical in gaining a deeper understanding of the potential therapeutic effect of LTI-03.”
Read the DDW interview with Dr Muhunthan Thillai, CEO at Qureight.
Diana Spencer, Senior Digital Content Editor, DDW
